1,252 results on '"Gordon, Michael S"'
Search Results
2. Submillimeter-wavelength Polarimetry of IRC+10216
- Author
-
Andersson, B-G, Karoly, Janik, Bastien, Pierre, Soam, Archana, Coudé, Simon, Tahani, Mehrnoosh, Gordon, Michael S., and Fox-Middleton, Sydney
- Subjects
Astrophysics - Solar and Stellar Astrophysics ,Astrophysics - Astrophysics of Galaxies - Abstract
We present SCUBA-2/POL-2 850 $\mu$m polarimetric observations of the circumstellar envelope (CSE) of the carbon-rich asymptotic giant branch (AGB) star IRC+10216. Both FIR and optical polarization data indicate grains aligned with their long axis in the radial direction relative to the central star. The 850 $\mu$m polarization does not show this simple structure. The 850 $\mu$m data are indicative, albeit not conclusive, of a magnetic dipole geometry. Assuming such a simple dipole geometry, the resulting 850 $\mu$m polarization geometry is consistent with both Zeeman observations and small-scale structure in the CSE. While there is significant spectral line polarization contained within the SCUBA-2 850 $\mu$m pass-band for the source, it is unlikely that our broadband polarization results are dominated by line polarization. To explain the required grain alignment, grain mineralogy effects, due to either fossil silicate grains from the earlier oxygen-rich AGB phase of the star, or due to the incorporation of ferromagnetic inclusions in the largest grains, may play a role. We argue that the most likely explanation is due to a new alignment mechanism \citep{arXiv:2009.11304} wherein a charged grain, moving relative to the magnetic field, precesses around the induced electric field and therefore aligns with the magnetic field. This mechanism is particularly attractive as the optical, FIR, and sub-mm wave polarization of the carbon dust can then be explained in a consistent way, differing simply due to the charge state of the grains., Comment: Accepted in ApJ v2 - title update to match published manuscript
- Published
- 2023
3. How Well Do We Know Our Own Conscious Experience? The Case of Human Echolocation
- Author
-
Schwitzgebel, Eric and Gordon, Michael S
- Subjects
Psychology: Perceptual Cognitive Psychology ,Philosophy: Epistemology ,Philosophy: Philosophy of Mind ,Perceptual Cognitive Psychology ,Epistemology ,Philosophy of Mind - Abstract
Researchers from the 1940's through the present have found that normal, sighted people can echolocate - that is, detect properties of silent objects by attending to sound reflected from them. We argue that echolocation is a normal part of our conscious, perceptual experience. Despite this, we argue that people are often grossly mistaken about their experience of echolocation. If so, echolocation provides a counterexample to the view that we cannot be seriously mistaken about our own current conscious experience.
- Published
- 2000
4. Extended-release buprenorphine induction in opioid non-tolerant incarcerated individuals
- Author
-
Gordon, Michael S., Blue, Thomas R., Vocci, Frank J., Mitchell, Shannon G., Wenzel, Kevin R., and Fishman, Marc
- Published
- 2024
- Full Text
- View/download PDF
5. The Self-Efficacy Questionnaire for Depressed Adolescents : a measure to predict the course of depression in depressed youth
- Author
-
Gordon, Michael S, Tonge, Bruce J., and Melvin, Glenn A.
- Published
- 2012
6. Evaluating the Effect of Parent–Child Interactive Groups in a School-Based Parent Training Program: Parenting Behavior, Parenting Stress and Sense of Competence
- Author
-
Buchanan-Pascall, Sarah, Melvin, Glenn A., Gordon, Michael S., and Gray, Kylie M.
- Published
- 2023
- Full Text
- View/download PDF
7. Outcome of adolescent depression : 6 months after treatment
- Author
-
Gordon, Michael S, Tonge, Bruce J., and Melvin, Glenn A.
- Published
- 2011
8. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid TumorsDilpacimab in Patients with Advanced Solid Tumors
- Author
-
Gordon, Michael S, Nemunaitis, John, Barve, Minal, Wainberg, Zev A, Hamilton, Erika P, Ramanathan, Ramesh K, Sledge, George W, Yue, Huibin, Morgan-Lappe, Susan E, Blaney, Martha, Kasichayanula, Sreeneeranj, Motwani, Monica, Wang, Lan, Naumovski, Louie, and Strickler, John H
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Ovarian Cancer ,Clinical Trials and Supportive Activities ,Orphan Drug ,Cancer ,Rare Diseases ,Patient Safety ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adaptor Proteins ,Signal Transducing ,Adult ,Aged ,Antibodies ,Bispecific ,Antineoplastic Agents ,Calcium-Binding Proteins ,Female ,Follow-Up Studies ,Humans ,Male ,Maximum Tolerated Dose ,Middle Aged ,Neoplasms ,Prognosis ,Tissue Distribution ,Vascular Endothelial Growth Factor A ,Pharmacology and Pharmaceutical Sciences ,Oncology & Carcinogenesis ,Biochemistry and cell biology ,Oncology and carcinogenesis - Abstract
Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from a phase I study (trial registration ID: NCT01946074) of dilpacimab in patients with advanced solid tumors. Eligible patients (≥18 years) received dilpacimab intravenously on days 1 and 15 in 28-day cycles at escalating dose levels (range, 1.25-7.5 mg/kg) until progressive disease or unacceptable toxicity. As of August 2018, 55 patients with solid tumors were enrolled in the dilpacimab monotherapy dose-escalation and dose-expansion cohorts. The most common treatment-related adverse events (TRAE) included hypertension (60.0%), headache (30.9%), and fatigue (21.8%). A TRAE of special interest was gastrointestinal perforation, occurring in 2 patients (3.6%; 1 with ovarian and 1 with prostate cancer) and resulting in 1 death. The PK of dilpacimab showed a half-life ranging from 4.9 to 9.5 days, and biomarker analysis demonstrated that the drug bound to both VEGF and DLL4 targets. The recommended phase II dose for dilpacimab monotherapy was established as 3.75 mg/kg, primarily on the basis of tolerability through multiple cycles. A partial response was achieved in 10.9% of patients (including 4 of 16 patients with ovarian cancer). The remaining patients had either stable disease (52.7%), progressive disease (23.6%), or were deemed unevaluable (12.7%). These results demonstrate that dilpacimab monotherapy has an acceptable safety profile, with clinical activity observed in patients with advanced solid tumors.
- Published
- 2021
9. Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors
- Author
-
Jimeno, Antonio, Baranda, Joaquina, Iams, Wade T., Park, Jong Chul, Mita, Monica, Gordon, Michael S., Taylor, Matthew, Dhani, Neesha, Leal, Alexis D., Neupane, Prakash, Eng, Cathy, Yeku, Oladapo, Mita, Alain, Moser, Justin C., Butler, Marcus, Loughhead, Scott M., Jennings, Julia, Miselis, Nathan R., Ji, Rui-Ru, Nair, Nitya, Kornacker, Martin, Zwirtes, Ricardo F., Bernstein, Howard, and Sharei, Armon
- Published
- 2023
- Full Text
- View/download PDF
10. On the collisional disalignment of dust grains in illuminated and shaded regions of IC 63
- Author
-
Soam, Archana, Andersson, B-G, Acosta-Pulido, Jose, López, Manuel Fernández, Vaillancourt, John E., Weaver, Susanna L. Widicus, Piirola, Vilppu, and Gordon, Michael S.
- Subjects
Astrophysics - Astrophysics of Galaxies - Abstract
Interstellar dust grain alignment causes polarization from UV to mm wavelengths, allowing the study of the geometry and strength of the magnetic field. Over last couple of decades observations and theory have led to the establishment of the Radiative Alignment Torque (RAT) mechanism as leading candidate to explain the effect. With a quantitatively well constrained theory, polarization can be used not only to study the interstellar magnetic field, but also the dust and other environmental parameters. Photo-dissociation Regions (PDRs), with their intense, anisotropic radiation fields, consequent rapid $\rm H_{2}$ formation, and high spatial density-contrast provide a rich environment for such studies. Here we discuss an expanded optical, NIR, and mm-wave study of the IC\,63 nebula, showing strong $\rm H_{2}$ formation-enhanced alignment and the first direct empirical evidence for disalignment due to gas-grain collisions using high-resolution $\rm HCO^{+}$(J=1-0) observations. We find that relative amount of polarization is marginally anti-correlated with column density of $\rm HCO^{+}$. However, separating the lines of sight of optical polarimetry into those behind, or in front of, a dense clump as seen from $\gamma$ Cas, the distribution separates into two well defined sets, with data corresponding to \enquote{shaded} gas having a shallower slope. This is expected if the decrease in polarization is caused by collisions since collisional disalignment rate is proportional to R$_C\propto n\sqrt{T}$. Ratios of the best-fit slopes for the \enquote{illuminated} and \enquote{shaded} samples of lines of sight agrees, within the uncertainties, with the square-root of the two-temperature H$_2$ excitation in the nebula seen by Thi et al. (2009)., Comment: 14 pages, 6 figures, Accepted for publication in ApJ
- Published
- 2020
- Full Text
- View/download PDF
11. Red Supergiants, Yellow Hypergiants, and Post-RSG Evolution
- Author
-
Gordon, Michael S. and Humphreys, Roberta M.
- Subjects
Astrophysics - Solar and Stellar Astrophysics ,Astrophysics - Astrophysics of Galaxies - Abstract
How massive stars end their lives remains an open question in the field of star evolution. While the majority of stars above 9 M_sun will become red supergiants (RSGs), the terminal state of these massive stars can be heavily influenced by their mass-loss histories. Periods of enhanced circumstellar wind activity can drive stars off the RSG branch of the HR Diagram. This phase, known as post-RSG evolution, may well be tied to high mass-loss events or eruptions as seen in the Luminous Blue Variables and other massive stars. This article highlights some of the recent observational and modeling studies that seek to characterize this unique class of stars, the post-RSGs, and link them to other massive objects on the HR Diagram such as LBVs, Yellow Hypergiants, and dusty RSGs., Comment: Published in "Luminous stars in Nearby Galaxies." https://www.mdpi.com/journal/galaxies/special_issues/Luminous
- Published
- 2020
- Full Text
- View/download PDF
12. Exploring the Mass Loss Histories of the Red Supergiants
- Author
-
Humphreys, Roberta M., Helmel, Greta, Jones, Terry J., and Gordon, Michael S.
- Subjects
Astrophysics - Solar and Stellar Astrophysics ,Astrophysics - Astrophysics of Galaxies - Abstract
We report mid- to far-infrared imaging and photomety from 7 to 37 microns with SOFIA/FORCAST and 2 micron adaptive optics imaging with LBTI/LMIRCam of a large sample of red supergiants (RSGs) in four Galactic clusters; RSGC1, RSGC2=Stephenson 2, RSGC3, and NGC 7419. The red supergiants in these clusters cover their expected range in luminosity and initial mass from approximately 9 to more than 25 Solar masses. The population includes examples of very late-type RSGs such as MY Cep which may be near the end of the RSG stage, high mass losing maser sources, yellow hypergiants and post-RSG candidates. Many of the stars and almost all of the most luminous have spectral energy distributions (SEDs) with extended infrared excess radiation at the longest wavelengths. To best model their SEDs we use DUSTY with a variable radial density distribution function to estimate their mass loss rates. Our mass loss rate -- luminosity relation for 42 RSGs basically follows the classical de Jager curve, but at luminosities below 10^5 Solar luminosities we find a significant population of red supergiants with mass loss rate below the de Jager relation. At luminosities above 10^5 Solar luminosities there is a rapid transition to higher mass loss rates that approximates and overlaps the de Jager curve. We recommend that instead of using a linear relation or single curve, the empirical mass loss rate -- luminosity relation is better represented by a broad band. Interestingly, the transition to much higher mass loss rates at about 10^5 Lsun corresponds approximately to an initial mass of 18 --20 Msun which is close to the upper limit for RSGs becoming Type II SNe., Comment: Accepted for publication in the Astronomical Journal
- Published
- 2020
- Full Text
- View/download PDF
13. Continuing Care App for Probationers and Parolees with Substance Use Disorders
- Author
-
Carswell, Steven B., Gordon, Michael S., Gryczynski, Jan, Taxman, Faye S., Schadegg, Mary, Ferguson, Kaitlin N., and Maher, Kelly
- Abstract
This pilot proof-of-concept study examined the feasibility and acceptability of a Continuing Care mobile application (app) designed to meet the recovery and personal support needs of individuals under justice supervision who were receiving outpatient substance use disorder (SUD) treatment. The study included adults on probation or parole who were enrolled in an outpatient SUD treatment program (N = 15; 86.7% males). Participants were instructed to utilize the Continuing Care app daily for 4 weeks. At the end of the study, they completed a satisfaction questionnaire. Of the 15 participants enrolled in the study, 12 (80%) completed the Continuing Care app modules and the satisfaction questionnaire, and all of these participants indicated high levels of satisfaction with the app (on a scale of 1-10, Mean = 1.8, SD = 1.2). The Continuing Care app was well-utilized and perceived as valuable by this group of low-income, underserved, and hard-to-reach individuals. Further research is needed to refine app content and evaluate its ability to meaningfully enhance and extend the benefits of SUD treatment.
- Published
- 2022
- Full Text
- View/download PDF
14. ALMA polarimetry measures magnetically aligned dust grains in the torus of NGC 1068
- Author
-
Lopez-Rodriguez, Enrique, Alonso-Herrero, Almudena, García-Burillo, Santiago, Gordon, Michael S., Ichikawa, Kohei, Imanishi, Masatoshi, Kameno, Seiji, Levenson, Nancy A., Nikutta, Robert, and Packham, Chris
- Subjects
Astrophysics - Astrophysics of Galaxies - Abstract
The obscuring structure surrounding active galactic nuclei (AGN) can be explained as a dust and gas flow cycle that fundamentally connects the AGN with their host galaxies. This structure is believed to be associated with dusty winds driven by radiation pressure. However, the role of magnetic fields, which are invoked in almost all models for accretion onto a supermassive black hole and outflows, is not thoroughly studied. Here we report the first detection of polarized thermal emission by means of magnetically aligned dust grains in the dusty torus of NGC 1068 using ALMA Cycle 4 polarimetric dust continuum observations ($0.07"$, $4.2$ pc; 348.5 GHz, $860$ $\mu$m). The polarized torus has an asymmetric variation across the equatorial axis with a peak polarization of $3.7\pm0.5$\% and position angle of $109\pm2^{\circ}$ (B-vector) at $\sim8$ pc east from the core. We compute synthetic polarimetric observations of magnetically aligned dust grains assuming a toroidal magnetic field and homogeneous grain alignment. We conclude that the measured 860 $\mu$m continuum polarization arises from magnetically aligned dust grains in an optically thin region of the torus. The asymmetric polarization across the equatorial axis of the torus arises from 1) an inhomogeneous optical depth, and 2) a variation of the velocity dispersion, i.e. variation of the magnetic field turbulence at sub-pc scales, from the eastern to the western region of the torus. These observations and modeling constrain the torus properties beyond spectral energy distribution results. This study strongly supports that magnetic fields up to a few pc contribute to the accretion flow onto the active nuclei., Comment: 19 pages, 11 figures (Accepted for Publication to ApJ)
- Published
- 2019
- Full Text
- View/download PDF
15. The Unexpected Spectrum of the Innermost Ejecta of the Red Hypergiant VY CMa
- Author
-
Humphreys, Roberta M., Ziurys, L. M., Bernal, J. J., Gordon, Michael S., Helton, L. Andrew, Ishibashi, Kazunori, Jones, Terry J., Richards, A. M. S., and Vlemmings, Wouter
- Subjects
Astrophysics - Solar and Stellar Astrophysics - Abstract
HST/STIS spectra of the small clumps and filaments closest to the central star in VY CMa reveal that the very strong K I emission and TiO and VO molecular emission, long thought to form in a dusty circumstellar shell, actually originate in a few small clumps 100's of AU from the star. The K I lines are 10 to 20 times stronger in these nearest ejecta than on the star. The observations also confirm VO as a circumstellar molecule. In this letter we discuss the spectra of the features, their motions and ages, and the identification of the molecular emission. The strength of the atomic and molecular features in the small clumps present an astrophysical problem for the excitation process. We show that the clumps must have a nearly clear line of sight to the star's radiation., Comment: To appear in the Astrophysical Journal
- Published
- 2019
- Full Text
- View/download PDF
16. BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
- Author
-
Middleton, Gary, Yang, Yiqun, Campbell, Catarina D, André, Thierry, Atreya, Chloe E, Schellens, Jan HM, Yoshino, Takayuki, Bendell, Johanna C, Hollebecque, Antoine, McRee, Autumn J, Siena, Salvatore, Gordon, Michael S, Tabernero, Josep, Yaeger, Rona, O'Dwyer, Peter J, De Vos, Filip, Van Cutsem, Eric, Millholland, John M, Brase, Jan C, Rangwala, Fatima, Gasal, Eduard, and Corcoran, Ryan B
- Subjects
Genetics ,Digestive Diseases ,Clinical Research ,Cancer ,Colo-Rectal Cancer ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers ,Tumor ,Colorectal Neoplasms ,ErbB Receptors ,Gene Expression Regulation ,Neoplastic ,Humans ,Imidazoles ,MAP Kinase Kinase 1 ,Mutation ,Oximes ,Panitumumab ,Prognosis ,Proto-Oncogene Proteins B-raf ,Pyridones ,Pyrimidinones ,Survival Rate ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeThe influence of the transcriptional and immunologic context of mutations on therapeutic outcomes with targeted therapy in cancer has not been well defined. BRAF V600E-mutant (BM) colorectal cancer comprises two main transcriptional subtypes, BM1 and BM2. We sought to determine the impact of BM subtype, as well as distinct biological features of those subtypes, on response to BRAF/MEK/EGFR inhibition in patients with colorectal cancer.Patients and methodsPaired fresh tumor biopsies were acquired at baseline and on day 15 of treatment from all consenting patients with BM colorectal cancer enrolled in a phase II clinical trial of dabrafenib, trametinib, and panitumumab. For each sample, BM subtype, cell cycle, and immune gene signature expression were determined using RNA-sequencing (RNA-seq), and a Cox proportional hazards model was applied to determine association with progression-free survival (PFS).ResultsConfirmed response rates, median PFS, and median overall survival (OS) were higher in BM1 subtype patients compared with BM2 subtype patients. Evaluation of immune contexture identified greater immune reactivity in BM1, whereas cell-cycle signatures were more highly expressed in BM2. A multivariate model of PFS incorporating BM subtype plus immune and cell-cycle signatures revealed that BM subtype encompasses the majority of the effect.ConclusionsBM subtype is significantly associated with the outcome of combination dabrafenib, trametinib, and panitumumab therapy and may serve as a standalone predictive biomarker beyond mutational status. Our findings support a more nuanced approach to targeted therapeutic decisions that incorporates assessment of transcriptional context.
- Published
- 2020
17. Luminous and Variable Stars in NGC 2403 and M81
- Author
-
Humphreys, Roberta M., Stangl, Sarah, Gordon, Michael S., Davidson, Kris, and Grammer, Skyler H.
- Subjects
Astrophysics - Solar and Stellar Astrophysics - Abstract
We present the results of spectroscopy and multi-wavelength photometry of luminous and variable star candidates in the nearby spiral galaxies NGC 2403 and M81. We discuss specific classes of stars, the Luminous Blue Variables (LBVs), B[e] supergiants (sgB[e]), and the high luminosity yellow hypergiants. We identify two new LBV candidates, and three sgB[e] stars in M81. We also find that some stars previously considered LBV candidates are actually field stars. The confirmed and candidate LBVs and sgB[e] stars together with the other confirmed members are shown on the HR Diagrams for their respective galaxies. We also present the HR Diagrams for the two "SN impostors", V37 (SN2002kg) and V12(SN1954J) in NGC 2403 and the stars in their immediate environments., Comment: To appear in the Astronomical Journal
- Published
- 2018
- Full Text
- View/download PDF
18. Thermal Emission in the Southwest Clump of VY CMa
- Author
-
Gordon, Michael S., Jones, Terry J., Humphreys, Roberta M., Ertel, Steve, Hinz, Philip M., Hoffmann, William F., Stone, Jordan, Spalding, Eckhart, and Vaz, Amali
- Subjects
Astrophysics - Solar and Stellar Astrophysics ,Astrophysics - Astrophysics of Galaxies - Abstract
We present high spatial resolution LBTI/NOMIC $9-12$ $\mu m$ images of VY CMa and its massive outflow feature, the Southwest (SW) Clump. Combined with high-resolution imaging from HST ($0.4-1$ $\mu m$) and LBT/LMIRCam ($1-5$ $\mu m$), we isolate the spectral energy distribution (SED) of the clump from the star itself. Using radiative-transfer code DUSTY, we model both the scattered light from VY CMa and the thermal emission from the dust in the clump to estimate the optical depth, mass, and temperature of the SW Clump. The SW Clump is optically thick at 8.9 $\mu m$ with a brightness temperature of $\sim$200 K. With a dust chemistry of equal parts silicates and metallic iron, as well as assumptions on grain size distribution, we estimate a dust mass of $5.4\times10^{-5}\,M_\odot$. For a gas--to--dust ratio of 100, this implies a total mass of $5.4\times10^{-3}\,M_\odot$. Compared to the typical mass-loss rate of VY CMa, the SW Clump represents an extreme, localized mass-loss event from $\lesssim300$ years ago., Comment: Published in AJ, February 2019. 14 pages, 5 figures, 2 tables
- Published
- 2018
- Full Text
- View/download PDF
19. A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer
- Author
-
Maurice-Dror, Corinne, Le Moigne, Ronan, Vaishampayan, Ulka, Montgomery, Robert B., Gordon, Michael S., Hong, Nan Hyung, DiMascio, Leah, Perabo, Frank, and Chi, Kim N.
- Published
- 2022
- Full Text
- View/download PDF
20. Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Results From a Phase 1b Trial
- Author
-
Wong, Deborah J., Bauer, Todd M., Gordon, Michael S., Bene-Tchaleu, Fabiola, Zhu, Jing, Zhang, Xiaosong, and Cha, Edward
- Published
- 2022
- Full Text
- View/download PDF
21. A Tale of Two Impostors: SN2002kg and SN1954J in NGC 2403
- Author
-
Humphreys, Roberta M., Davidson, Kris, Van Dyk, Schuyler D., and Gordon, Michael S.
- Subjects
Astrophysics - Solar and Stellar Astrophysics - Abstract
We describe new results on two supernova impostors in NGC 2403, SN 1954J(V12) and SN 2002kg(V37). For the famous object SN 1954J we combine four critical observations: its current SED, its Halpha emission line profile, the Ca II triplet in absorption in its red spectrum, and the brightness compared to its pre-event state. Together these strongly suggest that the survivor is now a hot supergiant with T ~ 20000 K, a dense wind, substantial circumstellar extinction, and a G-type supergiant companion. The hot star progenitor of V12's giant eruption was likely in the post-red supergiant stage and had already shed a lot of mass. V37 is a classical LBV/S Dor variable. Our photometry and spectra observed during and after its eruption show that its outburst was an apparent transit on the HR Diagram due to enhanced mass loss and the formation of a cooler, dense wind. V37 is an evolved hot supergiant at ~10^6 Lsun with a probable initial mass of 60 -80 Msun., Comment: To appear in the Astrophysical Journal
- Published
- 2017
- Full Text
- View/download PDF
22. Searching for Cool Dust: II. Infrared Imaging of the OH/IR Supergiants, NML Cyg, VX Sgr, S Per and the Normal Red Supergiants RS Per and T Per
- Author
-
Gordon, Michael S., Humphreys, Roberta M., Jones, Terry J., Shenoy, Dinesh, Gehrz, Robert D., Helton, L. Andrew, Marengo, Massimo, Hinz, Philip M., and Hoffman, William F.
- Subjects
Astrophysics - Solar and Stellar Astrophysics - Abstract
New MMT/MIRAC (9-11 {\mu}m), SOFIA/FORCAST (11-37 {\mu}m), and Herschel/PACS (70 and 160 {\mu}m) infrared (IR) imaging and photometry is presented for three famous OH/IR red supergiants (NML Cyg, VX Sgr, and S Per) and two normal red supergiants (RS Per and T Per). We model the observed spectral energy distributions (SEDs) using radiative transfer code DUSTY. Azimuthal average profiles from the SOFIA/FORCAST imaging, in addition to dust mass distribution profiles from DUSTY, constrain the mass-loss histories of these supergiants. For all of our observed supergiants, the DUSTY models suggest that constant mass-loss rates do not produce enough dust to explain the observed infrared emission in the stars' SEDs. Combining our results with Shenoy et al. (2016) (Paper I) we find mixed results with some red supergiants showing evidence for variable and high mass-loss events while others have constant mass loss over the past few thousand years., Comment: 29 pages, 15 figures, 3 tables. Accepted to AJ
- Published
- 2017
- Full Text
- View/download PDF
23. The daily progress system - a recovery support tool to improve engagement and retention in outpatient substance use treatment.
- Author
-
Carswell, Steven B., Gordon, Michael S., Gryczynski, Jan, Horodyski, Ashley M., Ferguson, Kaitlin N., Maher, Kelly M., and Vocci, Frank J.
- Subjects
METHADONE treatment programs ,PATIENT compliance ,WORLD Wide Web ,SUBSTANCE abuse ,MOTIVATIONAL interviewing ,AFRICAN Americans ,RESEARCH funding ,SUBSTANCE abuse treatment ,ALCOHOLISM counselors ,PILOT projects ,CRIMINALS ,DRUG abuse counselors ,GROUP psychotherapy ,DESCRIPTIVE statistics ,SURVEYS ,CONVALESCENCE ,SOCIAL support ,QUALITY assurance ,DRUGS ,CRIMINAL justice system ,PATIENT satisfaction ,COUNSELING ,COGNITIVE therapy ,BUPRENORPHINE ,NALTREXONE ,POVERTY - Abstract
Background: This pilot proof-of-concept study examined the feasibility and acceptability of the Daily Progress System (DPS), a web-based platform designed to improve treatment engagement and retention among clients in outpatient substance use treatment. Methods: The study included adults under justice supervision in the community (probation or parole) who were clients at an outpatient treatment program (N = 30; 60% males). Participants were instructed to utilize the DPS daily for 4 weeks. Incentives were paid to participants for using the platform. At the end of the study, they completed a post-satisfaction questionnaire. Results: Of the 30 participants enrolled in the study, 28 (93.3%) completed the post-satisfaction questionnaire. Overall, they were extremely satisfied with the platform as 21/30 (70.0%) logged into the DPS on a daily basis and completed at least 15 daily surveys or more over the 30-day study period and 27/28 (96.5%) would recommend that the participating treatment program use the platform as part of treatment for other clients. Conclusions: The DPS was well-utilized and perceived as valuable by this group of justice involved, low-income, underserved, and hard-to-reach individuals. Further research is needed to refine platform content and evaluate its ability to meaningfully enhance and extend the benefits of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer
- Author
-
Corcoran, Ryan B, André, Thierry, Atreya, Chloe E, Schellens, Jan HM, Yoshino, Takayuki, Bendell, Johanna C, Hollebecque, Antoine, McRee, Autumn J, Siena, Salvatore, Middleton, Gary, Muro, Kei, Gordon, Michael S, Tabernero, Josep, Yaeger, Rona, O'Dwyer, Peter J, Humblet, Yves, De Vos, Filip, Jung, A Scott, Brase, Jan C, Jaeger, Savina, Bettinger, Severine, Mookerjee, Bijoyesh, Rangwala, Fatima, and Van Cutsem, Eric
- Subjects
Digestive Diseases ,Colo-Rectal Cancer ,Cancer ,Good Health and Well Being ,Antineoplastic Combined Chemotherapy Protocols ,Colorectal Neoplasms ,Drug Resistance ,Neoplasm ,ErbB Receptors ,Female ,Humans ,Imidazoles ,MAP Kinase Signaling System ,Male ,Mitogen-Activated Protein Kinase Kinases ,Oximes ,Panitumumab ,Protein Kinase Inhibitors ,Proto-Oncogene Proteins B-raf ,Pyridones ,Pyrimidinones ,Oncology and Carcinogenesis - Abstract
Although BRAF inhibitor monotherapy yields response rates >50% in BRAFV600-mutant melanoma, only approximately 5% of patients with BRAFV600E colorectal cancer respond. Preclinical studies suggest that the lack of efficacy in BRAFV600E colorectal cancer is due to adaptive feedback reactivation of MAPK signaling, often mediated by EGFR. This clinical trial evaluated BRAF and EGFR inhibition with dabrafenib (D) + panitumumab (P) ± MEK inhibition with trametinib (T) to achieve greater MAPK suppression and improved efficacy in 142 patients with BRAFV600E colorectal cancer. Confirmed response rates for D+P, D+T+P, and T+P were 10%, 21%, and 0%, respectively. Pharmacodynamic analysis of paired pretreatment and on-treatment biopsies found that efficacy of D+T+P correlated with increased MAPK suppression. Serial cell-free DNA analysis revealed additional correlates of response and emergence of KRAS and NRAS mutations on disease progression. Thus, targeting adaptive feedback pathways in BRAFV600E colorectal cancer can improve efficacy, but MAPK reactivation remains an important primary and acquired resistance mechanism.Significance: This trial demonstrates that combined BRAF + EGFR + MEK inhibition is tolerable, with promising activity in patients with BRAFV600E colorectal cancer. Our findings highlight the MAPK pathway as a critical target in BRAFV600E colorectal cancer and the need to optimize strategies inhibiting this pathway to overcome both primary and acquired resistance. Cancer Discov; 8(4); 428-43. ©2018 AACR.See related commentary by Janku, p. 389See related article by Hazar-Rethinam et al., p. 417This article is highlighted in the In This Issue feature, p. 371.
- Published
- 2018
25. Massive Star Formation in the LMC. I. N159 and N160 Complexes
- Author
-
Gordon, Michael S., Jones, Terry J., Gehrz, Robert D., and Helton, L. Andrew
- Subjects
Astrophysics - Astrophysics of Galaxies ,Astrophysics - Solar and Stellar Astrophysics - Abstract
We present images and spectral energy distributions (SEDs) of massive young stellar objects (YSOs) in three star-forming H II regions of the Large Magellanic Cloud: N159A, N159 Papillon, and N160. We use photometry from SOFIA/FORCAST at 25.3--37.1 um to constrain model fits to the SEDs and determine luminosities, ages, and dust content of the embedded YSOs and their local environments. By placing these sources on mid-infrared color-magnitude and color-color diagrams, we analyze their dust properties and consider their evolutionary status. Since each object in the FORCAST images has an obvious bright near-infrared counterpart in Spitzer Space Telescope images, we do not find any evidence for new, very cool, previously-undiscovered Class 0 YSOs. Additionally, based on its mid-infrared colors and model parameters, N159A is younger than N160 and the Papillon. The nature of the first extragalactic protostars in N159, P1 and P2, is also discussed., Comment: 31 pages, 8 figures, 3 tables. Accepted for publication in ApJ, November 2016
- Published
- 2016
- Full Text
- View/download PDF
26. Luminous and Variable Stars in M31 and M33. IV. Luminous Blue Variables, Candidate LBVs, and the B[e] Supergiants; How to Tell Them Apart
- Author
-
Humphreys, Roberta M., Gordon, Michael S., Martin, John C., Weis, Kerstin, and Hahn, David
- Subjects
Astrophysics - Solar and Stellar Astrophysics - Abstract
In this series of papers we have presented the results of a spectroscopic survey of luminous and variable stars in the nearby spirals M31 and M33. In this paper, we present spectroscopy of 132 additional luminous stars, variables, and emission line objects. Most of the stars have emission line spectra, including LBVs and candidate LBVs, Fe II emission line stars and the B[e] supergiants, and the warm hypergiants. Many of these objects are spectroscopically similar and are often confused with each other. With this large spectroscopic data set including various types of emission line stars, we examine their similarities and differences and propose the following criteria that can be used to help distinguish these stars in future work: 1. The B[e] supergiants have emission lines of [O I] and [Fe II] in their spectra. Most of the spectroscopically confirmed sgB[e] stars also have warm circumstellar dust in their SEDs. 2. Confirmed LBVs do not have the [O I] emission lines in their spectra. Some LBVs have [Fe II] emission lines, but not all. Their SEDS shows free-free emission in the near-infrared but no evidence for warm dust. Their most important and defining characteristic is the S Dor-type variability. 3. The warm hypergiants spectroscopically resemble both the LBVs in their eruption or dense wind state and the B[e] supergiants. However, they are very dusty. Some have [Fe II] and [O I] emission in their spectra like the sgB[e] stars, but can be distinguished by their absorption line spectra characteristic of A and F-type supergiants. In contrast, the B[e] supergiant spectra have strong continua and few if any apparent absorption lines., Comment: 42 pages, 6 figures, 7 tables. Submitted to ApJ for publication, November 2016
- Published
- 2016
- Full Text
- View/download PDF
27. Multiple Outflows in the Giant Eruption of a Massive Star
- Author
-
Humphreys, Roberta M., Martin, John C., Gordon, Michael S., and Jones, Terry J.
- Subjects
Astrophysics - Solar and Stellar Astrophysics - Abstract
The supernova impostor PSN J09132750+7627410 in NGC 2748 reached a maximum luminosity of approximately -14 mag. It was quickly realized that its was not a true supernova, but another example of a non-terminal giant eruption. PSN J09132750+7627410 is distinguished by multiple P Cygni absorption minima in the Balmer emission lines that correspond to outflow velocities of -400, -1100, and -1600 km/s. Multiple outflows have been observed in only a few other objects. In this paper we describe the evolution of the spectrum and the P Cygni profiles for three months past maximum, the post-maximum formation of a cool, dense wind, and the identification of a possible progenitor. One of the possible progenitors is an infrared source. Its pre-eruption spectral energy distribution suggests a bolometric luminosity of -8.3 mag and a dust temperature of 780 degrees K. If it is the progenitor it is above the AGB limit unlike the intermediate luminosity red transients. The three P Cygni profiles could be due to ejecta from the current eruption, the wind of the progenitor, or previous mass loss events. We suggest that they were all formed as part of the same high mass loss event and are due to material ejected at different velocities or energies. We also suggest that multiple outflows during giant eruptions may be more common than reported., Comment: To appear in the Astrophysical Journal
- Published
- 2016
- Full Text
- View/download PDF
28. Luminous and Variable Stars in M31 and M33. III. The Yellow and Red Supergiants and Post-Red Supergiant Evolution
- Author
-
Gordon, Michael S., Humphreys, Roberta M., and Jones, Terry J.
- Subjects
Astrophysics - Solar and Stellar Astrophysics ,Astrophysics - Astrophysics of Galaxies - Abstract
Recent supernova and transient surveys have revealed an increasing number of non-terminal stellar eruptions. Though the progenitor class of these eruptions includes the most luminous stars, little is known of the pre-supernova mechanics of massive stars in their most evolved state, thus motivating a census of possible progenitors. From surveys of evolved and unstable luminous star populations in nearby galaxies, we select a sample of yellow and red supergiant candidates in M31 and M33 for review of their spectral characteristics and spectral energy distributions. Since the position of intermediate and late-type supergiants on the color-magnitude diagram can be heavily contaminated by foreground dwarfs, we employ spectral classification and multi-band photometry from optical and near-infrared surveys to confirm membership. Based on spectroscopic evidence for mass loss and the presence of circumstellar dust in their SEDs, we find that $30-40\%$ of the yellow supergiants are likely in a post-red supergiant state. Comparison with evolutionary tracks shows that these mass-losing, post-RSGs have initial masses between $20-40\,M_{\odot}$. More than half of the observed red supergiants in M31 and M33 are producing dusty circumstellar ejecta. We also identify two new warm hypergiants in M31, J004621.05+421308.06 and J004051.59+403303.00, both of which are likely in a post-RSG state., Comment: Accepted for publication in ApJ. 34 pages, 11 figures
- Published
- 2016
- Full Text
- View/download PDF
29. On the Social Traits of Luminous Blue Variables
- Author
-
Humphreys, Roberta M., Weis, Kerstin, Davidson, Kris, and Gordon, Michael S.
- Subjects
Astrophysics - Solar and Stellar Astrophysics - Abstract
In a recent paper, Smith and Tombleson (2015) state that the Luminous Blue Variables (LBVs) in the Milky Way and the Magellanic Clouds are isolated; that they are not spatially associated with young O-type stars. They propose a novel explanation that would overturn the standard view of LBVs. In this paper we test their hypothesis for the LBVs in M31 and M33 as well as the LMC and SMC. In M31 and M33, the LBVs are associated with luminous young stars and supergiants appropriate to their luminosities and positions on the HR Diagram. Moreover, in the Smith and Tombleson scenario most of the LBVs should be runaway stars, but the stars' velocities are consistent with their positions in the respective galaxies. In the Magellanic Clouds, those authors' sample was a mixed population. We reassess their analysis, removing seven stars that have no clear relation to LBVs. When we separate the more massive classical and the less luminous LBVs, the classical LBVs have a distribution similar to the late O-type stars, while the less luminous LBVs have a distribution like the red supergiants. None of the confirmed LBVs have high velocities or are candidate runaway stars. These results support the accepted description of LBVs as evolved massive stars that have shed a lot of mass, and are now close to their Eddington limit., Comment: To appear in the Astrophysical Journal With an expanded discussion of statistical errors
- Published
- 2016
- Full Text
- View/download PDF
30. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
- Author
-
Daud, Adil, Kluger, Harriet M, Kurzrock, Razelle, Schimmoller, Frauke, Weitzman, Aaron L, Samuel, Thomas A, Moussa, Ali H, Gordon, Michael S, and Shapiro, Geoffrey I
- Subjects
Humans ,Melanoma ,Uveal Neoplasms ,Skin Neoplasms ,Neoplasm Metastasis ,Anilides ,Pyridines ,Receptors ,Vascular Endothelial Growth Factor ,Antineoplastic Agents ,Withholding Treatment ,Survival Analysis ,Adult ,Aged ,Aged ,80 and over ,Middle Aged ,United States ,Israel ,Belgium ,Female ,Male ,Proto-Oncogene Proteins c-met ,cabozantinib ,metastatic melanoma ,uveal melanoma ,vascular endothelial growth factor receptor ,MET/VEGFR inhibitor ,bone metastases ,Receptors ,Vascular Endothelial Growth Factor ,and over ,Oncology & Carcinogenesis ,Oncology and Carcinogenesis ,Public Health and Health Services - Abstract
BackgroundA phase II randomised discontinuation trial assessed cabozantinib (XL184), an orally bioavailable inhibitor of tyrosine kinases including VEGF receptors, MET, and AXL, in a cohort of patients with metastatic melanoma.MethodsPatients received cabozantinib 100 mg daily during a 12-week lead-in. Patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumours (RECIST) at week 12 were randomised to cabozantinib or placebo. Primary endpoints were objective response rate (ORR) at week 12 and postrandomisation progression-free survival (PFS).ResultsSeventy-seven patients were enroled (62% cutaneous, 30% uveal, and 8% mucosal). At week 12, the ORR was 5%; 39% of patients had SD. During the lead-in phase, reduction in target lesions from baseline was seen in 55% of evaluable patients overall and in 59% of evaluable patients with uveal melanoma. Median PFS after randomisation was 4.1 months with cabozantinib and 2.8 months with placebo (hazard ratio of 0.59; P=0.284). Median PFS from study day 1 was 3.8 months, 6-month PFS was 33%, and median overall survival was 9.4 months. The most common grade 3/4 adverse events were fatigue (14%), hypertension (10%), and abdominal pain (8%). One treatment-related death was reported from peritonitis due to diverticular perforation.ConclusionsCabozantinib has clinical activity in patients with metastatic melanoma, including uveal melanoma. Further clinical investigation is warranted.
- Published
- 2017
31. A New Luminous Blue Variable in M31
- Author
-
Humphreys, Roberta M., Martin, John C., and Gordon, Michael S.
- Subjects
Astrophysics - Solar and Stellar Astrophysics - Abstract
We report the fifth confirmed Luminous Blue Variable/S Doradus variable in M31. In 2006, J004526.62+415006.3 had the spectrum of hot Fe II emission line star with strong P Cygni profiles in the Balmer lines. In 2010, its absorption line spectrum resembled an early A-type supergiant with H and Fe II emission lines with strong P Cygni profiles, and in 2013 the spectrum had fully transitioned to an F-type supergiant due to the formation of the optically thick, cool wind which characterizes LBVs at maximum light. The photometric record supports the LBV/S Dor nature of the variability. Its bolometric luminosity ~ -9.65 mag places it on the HR Diagram near the known LBVs, AE And, Var C in M33 and S Dor.
- Published
- 2015
- Full Text
- View/download PDF
32. Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.
- Author
-
Weaver, Alice N., Iams, Wade T., Park, Jong Chul, Mita, Monica, Holtick, Udo, Gordon, Michael S., Rodabaugh, Kerry J., Dhani, Neesha, Neupane, Prakash, Taylor, Matthew, Amanda Duvall, E., Jennings, Julia, Miselis, Nathan R., Loughhead, Scott, Warren, Marshelle S., Bernstein, Howard, Klussmann, Jens P., Baranda, Joaquina, and Jimeno, Antonio
- Published
- 2024
- Full Text
- View/download PDF
33. Phase II clinical trial of nab‐paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer.
- Author
-
Jameson, Gayle S., Hosein, Peter J., Pierce, Erin, Kamgar, Mandana, Gordon, Michael S., Snyder, Courtney, Roe, Denise J., Wertheim, Betsy C., Davey, Marina, Barrett, Michael T., Von Hoff, Daniel D., and Borazanci, Erkut
- Subjects
CISPLATIN ,PANCREATIC cancer ,GEMCITABINE ,KARNOFSKY Performance Status ,CLINICAL trials - Abstract
Background: A previous phase IB/II study of nab‐paclitaxel + cisplatin + gemcitabine (NABPLAGEM) in 25 patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrated favorable results. This phase II study was conducted to further evaluate the safety, efficacy, and impact on quality of life (QOL) of NABPLAGEM in a multi‐center setting. Methods: Participants were ≥18 years; had measurable PDAC; Karnofsky performance status of ≥70%; life expectancy ≥12 weeks;
- Published
- 2024
- Full Text
- View/download PDF
34. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer
- Author
-
Chiang, Anne C., Sequist, Lecia Van Dam, Gilbert, Jill, Conkling, Paul, Thompson, Dana, Marcoux, J. Paul, Gettinger, Scott, Kowanetz, Marcin, Molinero, Luciana, O’Hear, Carol, Fassò, Marcella, Lam, Sivuonthanh, and Gordon, Michael S.
- Published
- 2020
- Full Text
- View/download PDF
35. Submillimeter-wavelength Polarimetry of IRC+10216
- Author
-
Andersson, B-G., primary, Karoly, Janik, additional, Bastien, Pierre, additional, Soam, Archana, additional, Coudé, Simon, additional, Tahani, Mehrnoosh, additional, Gordon, Michael S., additional, and Fox-Middleton, Sydney, additional
- Published
- 2024
- Full Text
- View/download PDF
36. Paclitaxel protein bound (A) plus gemcitabine (G) plus cisplatin (C) and hydroxychloroquine (HCQ) neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC).
- Author
-
Borazanci, Erkut Hasan, primary, Jameson, Gayle S., additional, Snyder, Courtney Edwards, additional, Thosani, Amar, additional, Sckolnik, Steven, additional, Korn, Ronald Lee, additional, Rahmanuddin, Syed, additional, Mocan, Dan, additional, Pearse, Shelby, additional, Gordon, Michael S., additional, Von Hoff, Daniel D., additional, Modasi, Aryan, additional, and Amini, Albert, additional
- Published
- 2024
- Full Text
- View/download PDF
37. Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- Author
-
Massard, Christophe, Gordon, Michael S, Sharma, Sunil, Rafii, Saeed, Wainberg, Zev A, Luke, Jason, Curiel, Tyler J, Colon-Otero, Gerardo, Hamid, Omid, Sanborn, Rachel E, O'Donnell, Peter H, Drakaki, Alexandra, Tan, Winston, Kurland, John F, Rebelatto, Marlon C, Jin, Xiaoping, Blake-Haskins, John A, Gupta, Ashok, and Segal, Neil H
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Cancer ,Urologic Diseases ,Clinical Trials and Supportive Activities ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,Aged ,Aged ,80 and over ,Antibodies ,Monoclonal ,Antineoplastic Agents ,B7-H1 Antigen ,Biopsy ,Female ,Humans ,Immunohistochemistry ,Male ,Middle Aged ,Time Factors ,Treatment Outcome ,Urinary Bladder Neoplasms ,Urothelium ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
PurposeTo investigate the safety and efficacy of durvalumab, a human monoclonal antibody that binds programmed cell death ligand-1 (PD-L1), and the role of PD-L1 expression on clinical response in patients with advanced urothelial bladder cancer (UBC).MethodsA phase 1/2 multicenter, open-label study is being conducted in patients with inoperable or metastatic solid tumors. We report here the results from the UBC expansion cohort. Durvalumab (MEDI4736, 10 mg/kg every 2 weeks) was administered intravenously for up to 12 months. The primary end point was safety, and objective response rate (ORR, confirmed) was a key secondary end point. An exploratory analysis of pretreatment tumor biopsies led to defining PD-L1-positive as ≥ 25% of tumor cells or tumor-infiltrating immune cells expressing membrane PD-L1.ResultsA total of 61 patients (40 PD-L1-positive, 21 PD-L1-negative), 93.4% of whom received one or more prior therapies for advanced disease, were treated (median duration of follow-up, 4.3 months). The most common treatment-related adverse events (AEs) of any grade were fatigue (13.1%), diarrhea (9.8%), and decreased appetite (8.2%). Grade 3 treatment-related AEs occurred in three patients (4.9%); there were no treatment-related grade 4 or 5 AEs. One treatment-related AE (acute kidney injury) resulted in treatment discontinuation. The ORR was 31.0% (95% CI, 17.6 to 47.1) in 42 response-evaluable patients, 46.4% (95% CI, 27.5 to 66.1) in the PD-L1-positive subgroup, and 0% (95% CI, 0.0 to 23.2) in the PD-L1-negative subgroup. Responses are ongoing in 12 of 13 responding patients, with median duration of response not yet reached (range, 4.1+ to 49.3+ weeks).ConclusionDurvalumab demonstrated a manageable safety profile and evidence of meaningful clinical activity in PD-L1-positive patients with UBC, many of whom were heavily pretreated.
- Published
- 2016
38. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
- Author
-
Voss, Martin H., Gordon, Michael S., Mita, Monica, Rini, Brian, Makker, Vicky, Macarulla, Teresa, Smith, David C., Cervantes, Andrés, Puzanov, Igor, Pili, Roberto, Wang, Ding, Jalal, Shadia, Pant, Shubham, Patel, Manish R., Neuwirth, Rachel l., Enke, Aaron, Shou, Yaping, Sedarati, Farhad, Faller, Douglas V., and Burris, III, Howard A.
- Published
- 2020
- Full Text
- View/download PDF
39. The Atacama Cosmology Telescope: Cosmological parameters from three seasons of data
- Author
-
Sievers, Jonathan L., Hlozek, Renée A., Nolta, Michael R., Acquaviva, Viviana, Addison, Graeme E., Ade, Peter A. R., Aguirre, Paula, Amiri, Mandana, Appel, John William, Barrientos, L. Felipe, Battistelli, Elia S., Battaglia, Nick, Bond, J. Richard, Brown, Ben, Burger, Bryce, Calabrese, Erminia, Chervenak, Jay, Crichton, Devin, Das, Sudeep, Devlin, Mark J., Dicker, Simon R., Doriese, W. Bertrand, Dunkley, Joanna, Dünner, Rolando, Essinger-Hileman, Thomas, Faber, David, Fisher, Ryan P., Fowler, Joseph W., Gallardo, Patricio, Gordon, Michael S., Gralla, Megan B., Hajian, Amir, Halpern, Mark, Hasselfield, Matthew, Hernández-Monteagudo, Carlos, Hill, J. Colin, Hilton, Gene C., Hilton, Matt, Hincks, Adam D., Holtz, Dave, Huffenberger, Kevin M., Hughes, David H., Hughes, John P., Infante, Leopoldo, Irwin, Kent D., Jacobson, David R., Johnstone, Brittany, Juin, Jean Baptiste, Kaul, Madhuri, Klein, Jeff, Kosowsky, Arthur, Lau, Judy M, Limon, Michele, Lin, Yen-Ting, Louis, Thibaut, Lupton, Robert H., Marriage, Tobias A., Marsden, Danica, Martocci, Krista, Mauskopf, Phil, McLaren, Michael, Menanteau, Felipe, Moodley, Kavilan, Moseley, Harvey, Netterfield, Calvin B, Niemack, Michael D., Page, Lyman A., Page, William A., Parker, Lucas, Partridge, Bruce, Plimpton, Reed, Quintana, Hernan, Reese, Erik D., Reid, Beth, Rojas, Felipe, Sehgal, Neelima, Sherwin, Blake D., Schmitt, Benjamin L., Spergel, David N., Staggs, Suzanne T., Stryzak, Omelan, Swetz, Daniel S., Switzer, Eric R., Thornton, Robert, Trac, Hy, Tucker, Carole, Uehara, Masao, Visnjic, Katerina, Warne, Ryan, Wilson, Grant, Wollack, Ed, Zhao, Yue, and Zunckel, Caroline
- Subjects
Astrophysics - Cosmology and Nongalactic Astrophysics - Abstract
We present constraints on cosmological and astrophysical parameters from high-resolution microwave background maps at 148 GHz and 218 GHz made by the Atacama Cosmology Telescope (ACT) in three seasons of observations from 2008 to 2010. A model of primary cosmological and secondary foreground parameters is fit to the map power spectra and lensing deflection power spectrum, including contributions from both the thermal Sunyaev-Zeldovich (tSZ) effect and the kinematic Sunyaev-Zeldovich (kSZ) effect, Poisson and correlated anisotropy from unresolved infrared sources, radio sources, and the correlation between the tSZ effect and infrared sources. The power ell^2 C_ell/2pi of the thermal SZ power spectrum at 148 GHz is measured to be 3.4 +\- 1.4 muK^2 at ell=3000, while the corresponding amplitude of the kinematic SZ power spectrum has a 95% confidence level upper limit of 8.6 muK^2. Combining ACT power spectra with the WMAP 7-year temperature and polarization power spectra, we find excellent consistency with the LCDM model. We constrain the number of effective relativistic degrees of freedom in the early universe to be Neff=2.79 +\- 0.56, in agreement with the canonical value of Neff=3.046 for three massless neutrinos. We constrain the sum of the neutrino masses to be Sigma m_nu < 0.39 eV at 95% confidence when combining ACT and WMAP 7-year data with BAO and Hubble constant measurements. We constrain the amount of primordial helium to be Yp = 0.225 +\- 0.034, and measure no variation in the fine structure constant alpha since recombination, with alpha/alpha0 = 1.004 +/- 0.005. We also find no evidence for any running of the scalar spectral index, dns/dlnk = -0.004 +\- 0.012., Comment: 26 pages, 22 figures. This paper is a companion to Das et al. (2013) and Dunkley et al. (2013). Matches published JCAP version
- Published
- 2013
- Full Text
- View/download PDF
40. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap
- Author
-
Krawczyk, Noa, Buresh, Megan, Gordon, Michael S., Blue, Thomas R., Fingerhood, Michael I., and Agus, Deborah
- Published
- 2019
- Full Text
- View/download PDF
41. Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small-cell Lung Carcinoma
- Author
-
Hellerstedt, Beth A., Vogelzang, Nicholas J., Kluger, Harriet M., Yasenchak, Christopher A., Aftab, Dana T., Ramies, David A., Gordon, Michael S., and Lara, Primo, Jr.
- Published
- 2019
- Full Text
- View/download PDF
42. Antidepressant Medication: Is It a Viable and Valuable Adjunct to Cognitive-Behavioral Therapy for School Refusal?
- Author
-
Melvin, Glenn A. and Gordon, Michael S.
- Published
- 2019
- Full Text
- View/download PDF
43. Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations
- Author
-
Hussong, Andrea M., Gottfredson, Nisha C., Bauer, Dan J., Curran, Patrick J., Haroon, Maleeha, Chandler, Redonna, Kahana, Shoshana Y., Delaney, Joseph A.C., Altice, Frederick L., Beckwith, Curt G., Feaster, Daniel J., Flynn, Patrick M., Gordon, Michael S., Knight, Kevin, Kuo, Irene, Ouellet, Lawrence J., Quan, Vu M., Seal, David W., and Springer, Sandra A.
- Published
- 2019
- Full Text
- View/download PDF
44. A Sample of Candidate Radio Stars in FIRST and SDSS
- Author
-
Kimball, Amy E., Knapp, Gillian R., Ivezic, Zeljko, West, Andrew A., Bochanski, John J., Plotkin, Richard M., and Gordon, Michael S.
- Subjects
Astrophysics - Solar and Stellar Astrophysics - Abstract
We conduct a search for radio stars by combining radio and optical data from the Faint Images of the Radio Sky at Twenty cm survey (FIRST) and the Sloan Digital Sky Survey (SDSS). The faint limit of SDSS makes possible a homogeneous search for radio emission from stars of low optical luminosity. We select a sample of 112 candidate radio stars in the magnitude range $15
- Published
- 2009
- Full Text
- View/download PDF
45. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.
- Author
-
Hong, David S, Gordon, Michael S, Samlowski, Wolfram E, Kurzrock, Razelle, Tannir, Nizar, Friedland, David, Mendelson, David S, Vogelzang, Nicholas J, Rasmussen, Erik, Wu, Benjamin M, Bass, Michael B, Zhong, Zhandong D, Friberg, Gregory, and Appleman, Leonard J
- Subjects
Humans ,Carcinoma ,Renal Cell ,Kidney Neoplasms ,Phenylurea Compounds ,Niacinamide ,Pyrroles ,Indoles ,Angiogenic Proteins ,Recombinant Fusion Proteins ,Antineoplastic Combined Chemotherapy Protocols ,Treatment Outcome ,Adult ,Aged ,Middle Aged ,Female ,Male ,Biomarkers ,Tumor ,Sorafenib ,Sunitinib ,Angiogenesis ,Angiopoietins ,Targeted therapies ,Tie2 receptor ,Vascular growth factor receptor ,Cancer ,Clinical Research ,Clinical Trials and Supportive Activities ,Kidney Disease ,Oncology and Carcinogenesis ,Public Health and Health Services ,Oncology & Carcinogenesis - Abstract
BackgroundTrebananib, an investigational peptibody, binds to angiopoietin 1 and 2, thereby blocking their interaction with Tie2.Patients and methodsThis open-label phase I study examined trebananib 3 mg/kg or 10 mg/kg intravenous (I.V.) once weekly plus sorafenib 400 mg twice per day or sunitinib 50 mg once per day in advanced RCC. Primary end points were adverse event incidence and pharmacokinetics.ResultsThirty-seven patients were enrolled. During trebananib plus sorafenib administration (n = 17), the most common treatment-related adverse events (TRAEs) included rash (n = 12; 71%), diarrhea (n = 12; 71%), hypertension (n = 11; 65%), and fatigue (n = 11; 65%); grade ≥ 3 TRAEs (n = 7; 41%); and 2 patients (12%) had peripheral edema. During trebananib plus sunitinib administration (n = 19), the most common TRAEs included diarrhea (n = 14; 74%), fatigue (n = 13; 68%), hypertension (n = 11; 58%), and decreased appetite (n = 11; 58%); grade ≥ 3 TRAEs (n = 13; 68%); and 8 (42%) patients had peripheral edema. Trebananib did not appear to alter the pharmacokinetics of sorafenib or sunitinib. No patient developed anti-trebananib antibodies. Objective response rates were 29% (trebananib plus sorafenib) and 53% (trebananib plus sunitinib).ConclusionThe toxicities of trebananib 3 mg/kg or 10 mg/kg I.V. plus sorafenib or sunitinib in RCC were similar to those of sorafenib or sunitinib monotherapy, with peripheral edema being likely specific to the combinations. Antitumor activity was observed.
- Published
- 2014
46. 756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors
- Author
-
Spira, Alexander I, primary, Gordon, Michael S, additional, Henry, Jason, additional, Patel, Sandip P, additional, Sehgal, Kartik, additional, Sen, Shiraj, additional, Sweis, Randy, additional, Crochiere, Marsha, additional, He, Shui, additional, Smyrnios, Sondra, additional, Unadkat, Dipali, additional, Zhang, Bin, additional, and Tolcher, Anthony W, additional
- Published
- 2023
- Full Text
- View/download PDF
47. 594 SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16+tumors treated with cell-based vaccine, SQZ-PBMC-HPV
- Author
-
Jimeno, Antonio, primary, Iams, Wade T, additional, Park, Jong Chul, additional, MitaSc, Monica, additional, Holtick, Udo, additional, Gordon, Michael S, additional, Rodabaugh, Kerry J, additional, Dhani, Neesha, additional, Taylor, Matthew H, additional, Amanda Duvall, E, additional, Jennings, Julia, additional, Miselis, Nathan, additional, Loughhead, Scott, additional, Warren, Marshelle S, additional, Bernstein, Howard, additional, and Baranda, Joaquina, additional
- Published
- 2023
- Full Text
- View/download PDF
48. 692 COMMANDER-001: safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors
- Author
-
Pelster, Meredith, primary, Jimeno, Antonio, additional, Wise-Draper, Trisha, additional, Park, Jong Chul, additional, Villaflor, Victoria, additional, Rodabaugh, Kerry J, additional, Iams, Wade T, additional, Jennings, Julia, additional, Morrison, Melinda, additional, Miselis, Nathan, additional, Loughhead, Scott, additional, Bernstein, Howard, additional, Warren, Marshelle S, additional, Moser, Justin C, additional, and Gordon, Michael S, additional
- Published
- 2023
- Full Text
- View/download PDF
49. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors
- Author
-
Kim, Tae Won, primary, Bedard, Philippe L., additional, LoRusso, Patricia, additional, Gordon, Michael S., additional, Bendell, Johanna, additional, Oh, Do-Youn, additional, Ahn, Myung-Ju, additional, Garralda, Elena, additional, D’Angelo, Sandra P., additional, Desai, Jayesh, additional, Hodi, F. Stephen, additional, Wainberg, Zev, additional, Delord, Jean-Pierre, additional, Cassier, Phillippe A., additional, Cervantes, Andrés, additional, Gil-Martin, Marta, additional, Wu, Benjamin, additional, Patil, Namrata S., additional, Jin, Yanling, additional, Hoang, Tien, additional, Mendus, Diana, additional, Wen, Xiaohui, additional, Meng, Raymond, additional, and Cho, Byoung Chul, additional
- Published
- 2023
- Full Text
- View/download PDF
50. The daily progress system - a recovery support tool to improve engagement and retention in outpatient substance use treatment
- Author
-
Carswell, Steven B., primary, Gordon, Michael S., additional, Gryczynski, Jan, additional, Horodyski, Ashley M., additional, Ferguson, Kaitlin N., additional, Maher, Kelly M., additional, and Vocci, Frank J., additional
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.